Premium
Neuroleptic Malignant Syndrome with Risperidone
Author(s) -
Gleason Patrick P.,
Conigliaro Rosemarie L.
Publication year - 1997
Publication title -
pharmacotherapy: the journal of human pharmacology and drug therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.227
H-Index - 109
eISSN - 1875-9114
pISSN - 0277-0008
DOI - 10.1002/j.1875-9114.1997.tb03074.x
Subject(s) - neuroleptic malignant syndrome , risperidone , dopamine receptor d2 , bromocriptine , antipsychotic , medicine , extrapyramidal symptoms , blockade , extrapyramidal disorder , psychology , pharmacology , anesthesia , dopamine , psychiatry , schizophrenia (object oriented programming) , receptor , disease , prolactin , hormone
Neuroleptic malignant syndrome is thought to be a result of dopamine D 2 receptor blockade in the striatum of the basal ganglia. Risperidone, a benzisoxazole derivative antipsychotic, has high serotonin 5‐HT 2 receptor blockade and dose‐related D 2 receptor blockade. The high ratio is believed to impart the low frequency of extrapyramidal symptoms with risperidone at low dosages. With this low frequency of extrapyramidal symptoms, it was thought the frequency of neuroleptic malignant syndrome might also be lowered. A 73‐year‐old woman developed neuroleptic malignant syndrome after monotherapy with risperidone. The syndrome reversed after discontinuing risperidone and starting treatment with dantrolene and bromocriptine. It appears that the protection from extrapyramidal side effects observed with risperidone does not ensure protection from neuroleptic malignant syndrome.